Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics. Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans. The startup is focused on targeted oncology, or “precision medicine” for cancer, and will be headed by Gary Glick, who comes most recently from Boston-based IFM Therapeutics. There, he brought three immunotherapy drugs to clinical trials in three years, closing big pharmaceutical deals for their rights with Bristol Myers Squibb and Novartis.
Read more https://www.bostonglobe.com/2020/10/26/business/scorpion-launches-boston-with-108-million-go-after-targeted-cancer-drugs/